Fuller & Thaler Asset Management Inc. Acquires New Holdings in Hologic, Inc. (NASDAQ:HOLX)

Fuller & Thaler Asset Management Inc. bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 22,665 shares of the medical equipment provider’s stock, valued at approximately $1,634,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. General Partner Inc. acquired a new stake in Hologic in the fourth quarter worth $26,000. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Finally, Smithfield Trust Co grew its position in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 400 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Down 0.5 %

Shares of NASDAQ HOLX opened at $58.02 on Friday. The firm has a market capitalization of $13.02 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The stock has a 50 day moving average price of $61.02 and a 200 day moving average price of $70.06. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $55.89 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent research reports. Leerink Partnrs cut shares of Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Raymond James restated an “outperform” rating and issued a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Citigroup decreased their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Stephens restated an “overweight” rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.